Le marché des antipaludéens: entre régulation et défaillance
Résumé
Faced with the rise of resistance to monotherapies, the artemisinine-combination therapies (ACTs) have become the early�2000s, the golden standard in the fight against plasmodium falciparum malaria. Because of the need to substitute these therapies to older drugs and given the vastly more expensive ACTs, World Health Organization has established itself in global prescriber, enacting, on the one hand, health policy recommendations towards the endemic countries and organizing, on the other, a global supply chain. This article analyzes the disconnection that results from this model of governance, between the national and global levels and the consequences on the health status of malarious countries.